Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)
- Citation:
- J Clin Oncol vol 36 (Suppl) abstr 4556
- Meeting Instance:
- ASCO 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3176
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- RC Chen M Feuilly J Meng J Lister F Marteau M Morris D George T Choueiri
- Networks:
- CA043, LAPS-MA036, LAPS-NC010, PA018
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: